Market Pressure, Part I: Biotechs Feel the Chill
This article was originally published in Start Up
Executive Summary
Dismal conditions in the public capital markets can't help but affect biotech start-ups too. Venture capitalists are reassessing operating and exit strategies, and contemplating new business models.